|
82
|
278
|
4qyfA |
Chk1 kinase domain in complex with aminopyrazine compound 13 |
|
264
|
949
|
4ps7A |
Structure of pi3k gamma in complex with n-[6-(pyridin-3-yl)-1,3-benzothiazol-2-yl]acetamide |
|
113
|
501
|
4rgwA |
Crystal structure of a taf1-taf7 complex in human transcription factor iid |
|
97
|
285
|
4qmtA |
Mst3 in complex with hesperadin |
|
100
|
493
|
4qfrA |
Structure of ampk in complex with cl-a769662 activator and staurosporine inhibitor |
|
57
|
288
|
4rlpA |
Human p70s6k1 with ruthenium-based inhibitor fl772 |
|
96
|
540
|
4rerA |
Crystal structure of the phosphorylated human alpha1 beta2 gamma1 holo-ampk complex bound to amp and cyclodextrin |
|
92
|
348
|
4r8qA |
Structure and substrate recruitment of the human spindle checkpoint kinase bub1 |
|
317
|
1080
|
4ovuA |
Crystal structure of p110alpha in complex with nish2 of p85alpha |
|
17
|
90
|
4rsvA |
Human obscurin ig58 domain |
|
90
|
288
|
4qmyA |
Mst3 in complex with staurosporine |
|
157
|
490
|
4rgjA |
Apo crystal structure of cdpk4 from plasmodium falciparum, pf3d7_0717500 |
|
79
|
273
|
4rc2A |
Crystal structure of ser/thr kinase pim1 in complex with mitoxantrone derivatives |
|
78
|
271
|
4qyhA |
Chk1 kinase domain in complex with diazacarbazole gne-783 |
|
272
|
949
|
4ps8A |
Structure of pi3k gamma in complex with n-[6-(5,6-dimethoxypyridin-3-yl)-1,3-benzothiazol-2-yl]acetamide |
|
81
|
284
|
4rrvA |
Crystal structure of pdk1 in complex with atp and piftide |
|
88
|
284
|
4qmsA |
Mst3 in complex with dasatinib |
|
95
|
294
|
4rmzA |
Crystal structure of irak-4 |
|
145
|
478
|
4qoxA |
Crystal structure of cdpk4 from plasmodium falciparum, pf3d7_0717500 |
|
85
|
540
|
4rewA |
Crystal structure of the non-phosphorylated human alpha1 beta2 gamma1 holo-ampk complex |
|
90
|
345
|
4qpmA |
Structure of bub1 kinase domain |
|
106
|
329
|
4rllA |
Crystal structure of human ck2alpha in complex with the atp-competitive inhibitor 4-[(e)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoate |
|
93
|
281
|
4qo9A |
Mst3 in complex with danusertib |
|
78
|
340
|
4redA |
Crystal structure of human ampk alpha1 kd-aid with k43a mutation |
|
99
|
289
|
4qmmA |
Mst3 in complex with at-9283, 4-[(2-{4-[(cyclopropylcarbamoyl)amino]-1h-pyrazol-3-yl}-1h-benzimidazol-6-yl)methyl]morpholin-4-ium |
|
75
|
273
|
4rblA |
Crystal structure of ser/thr kinase pim1 in complex with mitoxantrone derivatives |
|
87
|
286
|
4rqkA |
Crystal structure of pdk1 in complex with atp and the pif-pocket ligand rs1 |
|
87
|
281
|
4qmlA |
Mst3 in complex with amp-pnp |
|
69
|
287
|
4rloA |
Human p70s6k1 with ruthenium-based inhibitor em5 |
|
88
|
288
|
4qmxA |
Mst3 in complex with saracatinib |
|
75
|
273
|
4rc4A |
Crystal structure of ser/thr kinase pim1 in complex with mitoxantrone derivatives |
|
79
|
271
|
4qygA |
Chk1 kinase domain in complex with diazacarbazole compound 14 |
|
273
|
949
|
4ps3A |
Structure of pi3k gamma in complex with 1-[6-(5-methoxypyridin-3-yl)-1,3-benzothiazol-2-yl]-3-[2-(1-propyl-1h-imidazol-4-yl)ethyl]urea |
|
90
|
285
|
4qnaA |
Mst3 in complex with 2-(4,6-diamino-1,3,5-triazin-2-yl)phenol |
|
80
|
273
|
4rpvA |
Co-crystal structure of pim1 with compound 3 |
|
114
|
330
|
4qtcA |
Structure of human haspin (gsg2) in complex with sch772984 revealing the first type-i binding mode |
|
96
|
287
|
4qmwA |
Mst3 in complex with pp-121, 1-cyclopentyl-3-(1h-pyrrolo[2,3-b]pyridin-5-yl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine |
|
277
|
1081
|
4ovvA |
Crystal structure of pi3kalpha in complex with dic4-pip2 |
|
100
|
287
|
4qmzA |
Mst3 in complex with sunitinib |
|
92
|
287
|
4qmuA |
Mst3 in complex with jnj-7706621, 4-({5-amino-1-[(2,6-difluorophenyl)carbonyl]-1h-1,2,4-triazol-3-yl}amino)benzenesulfonamide |
|
92
|
289
|
4qmoA |
Mst3 in complex with imidazolo-oxindole pkr inhibitor c16 |
|
76
|
273
|
4rc3A |
Crystal structure of ser/thr kinase pim1 in complex with mitoxantrone derivatives |
|
97
|
493
|
4qfsA |
Structure of ampk in complex with br2-a769662core activator and staurosporine inhibitor |
|
114
|
327
|
4rlkA |
Crystal structure of z. mays ck2alpha in complex with the atp-competitive inhibitor 4-[(e)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoate |
|
97
|
289
|
4qmvA |
Mst3 in complex with pf-03814735, n-{2-[(1s,4r)-6-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl]-2-oxoethyl}acetamide |
|
99
|
493
|
4qfgA |
Structure of ampk in complex with staurosporine inhibitor and in the absence of a synthetic activator |
|
74
|
272
|
4r5yA |
The complex structure of braf v600e kinase domain with a novel braf inhibitor |
|
80
|
278
|
4qyeA |
Chk1 kinase domain in complex with diarylpyrazine compound 1 |
|
86
|
289
|
4rqvA |
Crystal structure of pdk1 in complex with atp and the pif-pocket ligand rs2 |
|
95
|
290
|
4qmpA |
Mst3 in complex with cdk1/2 inhibitor iii, 5-amino-3-{[4-(aminosulfonyl)phenyl]amino}-n-(2,6-difluorophenyl)-1h-1,2,4-triazole-1-carbothioamide |
